Hetero Ring Containing Patents (Class 424/9.44)
  • Patent number: 12129235
    Abstract: The invention provides a compound of formula (I), and salts, solvates and radiolabelled forms thereof, together with complexes of the compound of formula (I) with TSPO, and methods for forming such complexes, and methods for detecting the compound of formula (I), such as in complex with TSPO.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: October 29, 2024
    Assignees: The University Court of the University of Glasgow, The University Court of the University of Edinburgh
    Inventors: Andrew Sutherland, Sally Pimlott, Adriana Tavares, Christoph Lucatelli
  • Patent number: 12098220
    Abstract: A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: September 24, 2024
    Assignee: Boston Scientific Medical Device Limited
    Inventors: Andrew Lennard Lewis, Jasmine Lord
  • Patent number: 11583596
    Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: February 21, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION
    Inventors: Olivier Meilhac, Emmanuelle Jestin, Florian Guibbal, Sébastien Benard
  • Patent number: 11045562
    Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Patent number: 10220100
    Abstract: The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 5, 2019
    Inventor: Keith R. Latham
  • Patent number: 9125822
    Abstract: A main object of the invention is to provide a particle for medical use which has an excellent capability of fixing a target biologically active substance and has such chemical and physical stability that the particle is less dissolved or deteriorated in a washing step. The present invention has solved the above problem with a particle for medical use having a layer containing a polymer compound formed on a surface of a core particle, wherein the polymer compound is a polymer comprising at least repeating units derived from an ethylenically unsaturated polymerizable monomer (a) having a functional group for fixing a biologically active substance, wherein the polymer has a reactive functional group on at least one terminal side thereof.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: September 8, 2015
    Assignee: SUMITOMO BAKELITE COMPANY, LTD.
    Inventors: Takayuki Matsumoto, Mitsutaka Matsumoto, Yoshiaki Fukunishi, Kazuya Kitagawa, Yuzo Hamaguchi
  • Publication number: 20150110722
    Abstract: The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalised with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system.
    Type: Application
    Filed: September 5, 2014
    Publication date: April 23, 2015
    Inventors: Stéphane HOHN, Andrew Lennard LEWIS, Sean Leo WILLIS, Matthew DREHER, Koorosh ASHRAFT, Yiqing TANG
  • Publication number: 20150056146
    Abstract: There is provided a composition used for contrast imaging, the composition containing an aqueous solution containing a J-aggregate of indocyanine green and at least one storage stabilizer selected from the group consisting of alkali metal ions, alkaline earth metal ions, and an ammonium ion.
    Type: Application
    Filed: August 15, 2014
    Publication date: February 26, 2015
    Inventor: Kouichi Kato
  • Patent number: 8916132
    Abstract: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: December 23, 2014
    Assignee: Servicios Cientificos Neuroinnovation Ltda
    Inventors: Rodrigo Kuljis Azocar, Ricardo Maccioni Baraona, Leonel Rojo
  • Publication number: 20140341812
    Abstract: Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure.
    Type: Application
    Filed: March 24, 2014
    Publication date: November 20, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Lisheng Cai, Victor W. Pike, Robert B. Innis
  • Publication number: 20140341813
    Abstract: To encapsulate indocyanine green (ICG) at a high concentration in a liposome without causing the agglomeration of ICG so that ICG remains as a monomer in an ICG-containing particle to be used as, for example, a contrast agent for fluorescence imaging or photoacoustic imaging, provided is a method of producing an indocyanine green-containing particle, including the step of mixing indocyanine green, a particle, and a solution containing 1 mM or more and 10 M or less of a chaotropic agent.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 20, 2014
    Applicant: CANON KABUSHIKI KAISHA
    Inventor: Yoshinori Tomida
  • Publication number: 20140341808
    Abstract: Compounds and a method for imaging myocardial perfusion, including administering to a patient a compound linked to an imaging moiety, wherein the compound binds MC-1, and scanning the patient using diagnostic imaging. Kits including the compound or precursor compounds linked or not linked to an imaging moiety are also described.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 20, 2014
    Applicant: RESPIRATORIUS AB
    Inventor: Martin Johansson
  • Patent number: 8877157
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: November 4, 2014
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Patent number: 8852553
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 7, 2014
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20140248213
    Abstract: The present invention provides for heptamethine cyanine dyes that possess both nuclear and near-infrared imaging capabilities. These dyes can be used for imaging, targeting and detecting tumors in patients.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 4, 2014
    Applicants: CEDARS-SINAI MEDICAL CENTER, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Leland W. K. Chung, Dongfeng Pan
  • Publication number: 20140241985
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Application
    Filed: June 13, 2012
    Publication date: August 28, 2014
    Applicant: CANCER TARGETED TECHNOLOGY LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Publication number: 20140227195
    Abstract: There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Yasuhiko Tabata, Masato Minami, Yoshinori Tomida, Satoshi Yuasa, Tetsuya Yano, Jun-ichiro Jo, Mie Morita
  • Patent number: 8795630
    Abstract: Compounds useful for the early diagnosis of malignant tumors, multiple sclerosis, and especially Alzheimer's Disease and related dementias; especially compounds of Formula (I) wherein R1 is selected from the group consisting of hydrogen, cyano, fluoro, iodo, alkyl, and aryl; R2 is selected from the group consisting of hydrogen, alkyl, and aryl; X is selected from the group consisting of CH2, CH2O, oxygen, OCH2, CH2S, SCH2, NH, N-alkyl, and N-aryl; Y is an optional spacer group, absent or selected from the group consisting of oxygen, sulfur, NH, N-alkyl, and N-aryl; and Z is selected from the group consisting of alkyl substituted with cyano, fluoro, or iodo and aryl substituted with cyano, fluoro, or iodo. In a preferred embodiment, R1 and R2 are hydrogen, X is CH2O, Y is absent, and Z is phenyl substituted with fluoro, cyano, or iodo. In some embodiments, Z is more specifically 18F-phenyl or 123I-phenyl or 131I-phenyl. Other compounds are also provided.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: August 5, 2014
    Assignee: Treventis Corporation
    Inventors: Sultan Darvesh, Eric Joy, Earl Martin, Ian Macdonald, Ian Pottie
  • Patent number: 8785396
    Abstract: A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 22, 2014
    Assignee: Mannkind Corporation
    Inventors: Andrea Leone-Bay, Grayson W. Stowell, Joseph J. Guarneri, Dawn M. Carlson, Marshall Grant, Chad C. Smutney
  • Publication number: 20140170066
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicants: Merck & Co., Inc., Visen Medical, Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Publication number: 20140161731
    Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: WisTa Laboratories Ltd.
    Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
  • Publication number: 20140154183
    Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 5, 2014
    Inventors: Matthias FRIEBE, Heribert SCHMITT-WILLICH, Matthias BERNDT, Ludger DINKELBORG, Norman KOGLIN, Keith GRAHAM
  • Publication number: 20140134105
    Abstract: The present invention relates to a composition and method for the detection of a detectable product formed from a compound of the present invention in the body of an individual. The detectable product may include a halide or a benzenetriol-based or benzenetetrol-based product of a dehalogenation reaction in the presence of FROS. In many embodiments, an indigo-like product formed from an indigogenic compound of the present invention may also be a detectable product for diagnostic purposes. This indigo-like product may have a higher residence time in tissues where it is formed, thus providing a detectable product localized to sites of high FROS. An indigogenic compound containing one or more radioactive isotopes is further provided for therapeutic purposes.
    Type: Application
    Filed: January 16, 2014
    Publication date: May 15, 2014
    Inventor: Keith R. Latham
  • Patent number: 8673269
    Abstract: The present invention relates to a composition and method for the detection of a detectable product formed from a compound of the present invention in the body of an individual. The detectable product may include a halide or a benzenetriol-based or benzenetetrol-based product of a dehalogenation reaction in the presence of FROS. In many embodiments, an indigo-like product formed from an indigogenic compound of the present invention may also be a detectable product for diagnostic purposes. This indigo-like product may have a higher residence time in tissues where it is formed, thus providing a detectable product localized to sites of high FROS. An indigogenic compound containing one or more radioactive isotopes is further provided for therapeutic purposes.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: March 18, 2014
    Inventor: Keith R. Latham
  • Publication number: 20140072513
    Abstract: The present invention relates to degradable polyacetal polymers having a C(O)—(CH2CH2O)n—R5 or a saccharide attached to amine radical of the backbone of the polymer, their polymer-active agent conjugates and their preparation processes, to compositions, and hydrogels containing them, as well as their use in therapy, diagnostic imaging and cosmetics.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 13, 2014
    Inventor: Oscar Peña Gulin
  • Publication number: 20140037542
    Abstract: A compound that includes a quaterrylene dye moiety as core, and a dendrimeric shell. For example, the compound may comprise at least four dendronized polyamides covalently attached to a quaterrylene dye. Also disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, comprising A(G)x, wherein: A comprises a quaterrylene dye; G comprises at least one functionalized dendrimeric structure; and x is 2 to 16. The compounds may be used for in methods for monitoring a therapeutic or diagnostic agent in a subject, or for treating a subject by administering the compound to the subject.
    Type: Application
    Filed: July 31, 2013
    Publication date: February 6, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mingfeng Bai, Pin Shao
  • Publication number: 20140017165
    Abstract: This invention relates generally to the discovery of novel nanoparticles for delivery of DNA double-stranded break (DSB) repair enzyme inhibitors such as wortmannin or wortmannin analogues. In one embodiment, these nanoparticles comprise a polylactide polyglycolide (PLGA) copolymer and a polyethylene glycol (PEG). In addition methods of treatment and methods of enhancing radiation treatments are also provided.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 16, 2014
    Inventors: Zhuang Wang, Michael Edward Pacold, Michael Edward Werner, Shrirang Karve
  • Publication number: 20140004051
    Abstract: The invention provides co-crystals and salts of contrast agents as well as methods to use and prepare the co-crystals and salts.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Inventor: Leonard R. MacGillivray
  • Patent number: 8562949
    Abstract: This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. This invention also relates to compounds, and methods of monitoring progression of a disease related to vesicular monoamine transporters.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: October 22, 2013
    Assignees: The Trustees of the University of Pennsylvania, The Regents of the University of Michigan, Avid Radiopharmaceuticals, Inc.
    Inventors: Hank F. Kung, Mei-Ping Kung, Michael Kilbourn, Daniel M. Skovronsky
  • Patent number: 8551452
    Abstract: This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 8, 2013
    Assignee: Massachusetts Institute of Technology
    Inventor: Richard Wurtman
  • Patent number: 8551449
    Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds of the formula R—Y—X—Z—R where each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties, Y and Z are urea and urethane groups and X is a alkylene group which may be further substituted. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: October 8, 2013
    Assignee: GE Healthcare AS
    Inventors: Duncan George Wynn, Ian Martin Newington, Harry John Wadsworth
  • Publication number: 20130045168
    Abstract: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.
    Type: Application
    Filed: October 24, 2012
    Publication date: February 21, 2013
    Applicant: FORIM-X AG
    Inventor: FORIM-X AG
  • Publication number: 20130039858
    Abstract: Novel fluorescent dye comprising metal oxide nanoparticles are prepared where the nanoparticles are as small as 3 nm or up to 7000 nm in diameter and where the dye is bound within the metal oxide matrix. In some embodiments the invention, novel dyes are covalently attached to the matrix and in other embodiments of the invention a dye is coordinate or ionic bound within the metal oxide matrix. A method for preparing the novel covalently bondable modified fluorescent dyes is presented. A method to prepare silica comprising nanoparticles that are 3 to 8 nm in diameter is presented. In some embodiments, the fluorescent dye comprising metal oxide nanoparticles are further decorated with functionality for use as multimodal in vitro or in vivo imaging agents. In other embodiments of the invention, the fluorescent dye comprising metal oxide nanoparticles provide therapeutic activity and incorporated therapeutic temperature monitoring.
    Type: Application
    Filed: February 24, 2011
    Publication date: February 14, 2013
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Scott Chang Brown, Amit Kumar Singh, Parvesh Sharma, Brij M. Moudgil, Stephen R. Grobmyer
  • Patent number: 8361438
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: January 29, 2013
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Publication number: 20130022549
    Abstract: The present invention relates to a composition and method for the detection of a detectable product formed from a compound of the present invention in the body of an individual. The detectable product may include a halide or a benzenetriol-based or benzenetetrol-based product of a dehalogenation reaction in the presence of FROS. In many embodiments, an indigo-like product formed from an indigogenic compound of the present invention may also be a detectable product for diagnostic purposes. This indigo-like product may have a higher residence time in tissues where it is formed, thus providing a detectable product localized to sites of high FROS. An indigogenic compound containing one or more radioactive isotopes is further provided for therapeutic purposes.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 24, 2013
    Inventor: Keith R. Latham
  • Publication number: 20120244079
    Abstract: The present invention provides nonradioactive NIR optical imaging agents based up on the structure of retinoid acid derivatives. The nonradioactive NIR optical imaging agent has been evaluated at the cellular level by confocal microscopy, and in vivo in a whole animal using a various xenograft models. The specific uptake of this agent in human cancer cells and multiple xenograft models demonstrate that nonradioactive near infrared dye labeled retinoid metabolites and/or analogs are useful for early stage cancer studies and diagnoses. Also, the present invention provides that nonradioactive near infrared dye labeled retinoid metabolites and/or analogs are useful for visualization of drug redistribution within the body which is useful in determining the optimal biological dose. Ultimately, the visualization data can be used as an analytical tool to reduce any systemic toxicity.
    Type: Application
    Filed: May 6, 2010
    Publication date: September 27, 2012
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Shi Ke, Michel Mawad, Wei Wang
  • Patent number: 8252778
    Abstract: Disclosed are compounds comprising the structure: In one aspect, the compounds exhibit maximum symmetric branching. Also disclosed are bilayers, micelles, coatings, and nanoparticles comprising the disclosed compounds. Also disclosed are processes for the preparation of the disclosed compounds and methods of using the disclosed compounds. Also disclosed are highly fluorinated dendrons and methods for making same. Also disclosed are methods for Fluorous Mixture Synthesis and tagging. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: August 28, 2012
    Assignee: University of Utah Research Foundation
    Inventors: Yihua Yu, Zhong-Xing Jiang
  • Publication number: 20120171116
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Application
    Filed: July 26, 2011
    Publication date: July 5, 2012
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Jane Wang, Bhaskara Rao Nallaganchu
  • Patent number: 8133472
    Abstract: Radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: March 13, 2012
    Assignee: Siemens Medical Solutions USA, Inc.
    Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Qianwa Liang
  • Publication number: 20120039816
    Abstract: Use of a radiolabelled form of 7-chloro-?/,?/,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4/-/-pyridazino[4,5-b]indole-1-acetamide as a biomarker for the detection, in an individual, of PBR levels associated with normal and pathological conditions. Method for the detection of PBR levels associated with normal and pathological conditions. Diagnostic kit.
    Type: Application
    Filed: October 27, 2009
    Publication date: February 16, 2012
    Applicants: SANOFI-AVENTIS, COMMISSARIAT A L'ENERGIE ATOMIQUE
    Inventors: Jesus Benavides, Hérve Boutin, Marie-Noëlle Castel, Annelaure Damont, Frédéric Dolle, Philippe Hantraye, Frank Marguet, Thomas Rooney, Luc Rivron, Bertrand Tavitian, Cyrille Thominiaux
  • Publication number: 20120039815
    Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds.
    Type: Application
    Filed: February 26, 2009
    Publication date: February 16, 2012
    Inventor: Hanno Priebe
  • Publication number: 20120039803
    Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an alkene or alkyne dienohile.
    Type: Application
    Filed: April 12, 2010
    Publication date: February 16, 2012
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Marc Stefan Robillard, Raffaella Rossin, Johan Lub, Pascal Renart Verkerk, Dirk Burdinski
  • Patent number: 8084018
    Abstract: Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a duration of about 30 minutes commencing at about 15 minutes after administration of labeled dopamine transporter ligand; and assessing, based on said SPECT acquisition, the amount of labeled dopamine transporter ligand that is bound to dopamine transporter.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 27, 2011
    Assignee: Alseres Pharmaceuticals, Inc.
    Inventor: Mark Hurtt
  • Publication number: 20110300072
    Abstract: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.
    Type: Application
    Filed: July 22, 2009
    Publication date: December 8, 2011
    Applicant: SERVICIOS CIENTIFICOS NEUROINNOVATION LTDA.
    Inventors: Ricardo Maccioni Baraona, Leonel Rojo, Rodrigo Kuljis Azocar
  • Publication number: 20110264027
    Abstract: Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl3.6H2O to oxidize the D ring and separating the resulting organic layer and drying.
    Type: Application
    Filed: February 19, 2009
    Publication date: October 27, 2011
    Applicant: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Chao Liu, Mahabeer Dobhal, William Potter, Janet Morgan, Allan Oseroff, Stephanie Pincus
  • Publication number: 20110250135
    Abstract: The invention relates to compounds of formula I, their synthesis and their use, in particular for detecting amyloid deposits in a patient.
    Type: Application
    Filed: September 4, 2009
    Publication date: October 13, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Heribert Schmitt-Willich, Ulrike Röhn, Matthias Friebe, Lutz Lehmann, Ansgar Fitzner, Sabine Krause, Damian Brockschnieder, Thomas Dyrks, Andrea Thiele, Ulf Bömer, Ursula Mönning, Tobias Heinrich
  • Publication number: 20110212026
    Abstract: Compounds useful for the early diagnosis of malignant tumors, multiple sclerosis, and especially Alzheimer's Disease and related dementias; especially compounds of Formula (I) wherein R1 is selected from the group consisting of hydrogen, cyano, fluoro, iodo, alkyl, and aryl; R2 is selected from the group consisting of hydrogen, alkyl, and aryl; X is selected from the group consisting of CH2, CH2O, oxygen, OCH2, CH2S, SCH2, NH, N-alkyl, and N-aryl; Y is an optional spacer group, absent or selected from the group consisting of oxygen, sulfur, NH, N-alkyl, and N-aryl; and Z is selected from the group consisting of alkyl substituted with cyano, fluoro, or iodo and aryl substituted with cyano, fluoro, or iodo. In a preferred embodiment, R1 and R2 are hydrogen, X is CH2O, Y is absent, and Z is phenyl substituted with fluoro, cyano, or iodo. In some embodiments, Z is more specifically 18F-phenyl or 123I-phenyl or 131I-phenyl. Other compounds are also provided.
    Type: Application
    Filed: August 28, 2009
    Publication date: September 1, 2011
    Inventors: Sultan Darvesh, Eric Joy, Earl Martin, Ian Macdonald, Ian Pottie
  • Publication number: 20110200535
    Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: August 5, 2009
    Publication date: August 18, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Lutz Lehmann, Andrea Thiele, Tobias Heinrich, Sonja Vollmer
  • Publication number: 20110165075
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: March 13, 2009
    Publication date: July 7, 2011
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Publication number: 20110142757
    Abstract: A compound of formula (I) wherein, X and Y independently bind TSPO, wherein X and Y are the same or different; and L is a linker that links X to Y; or a salt or solvate thereof. For preference, X and Y may be (II) or (III). The compounds may be radiolabeled with a radioisotope. Also methods for diagnosing or treating TSPO related disorders such as neurodegenerative disorder, inflammation or anxiety, eg. Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, multiple system atrophy, epilepsy, encephalopathy, stroke, brain tumour, anxiety, stress, emotional disturbances or cognitive impairment, glioblastoma, ischemic stroke, herpes encephalitis, HIV, amyotrophic lateral sclerosis, corticobasal degeneration, cancer, depression, an auto-immune disease and an infectious disease.
    Type: Application
    Filed: August 19, 2009
    Publication date: June 16, 2011
    Inventors: Michael Kassiou, Aaron Reynolds